Published in Proteomics Weekly, August 4th, 2008
The paper is the result of NIH-funded in vitro research conducted at the University of Vermont in Burlington, Vt., investigating two known phosphatidylinositol 3-kinase (PI3K) downstream proteins, Fra-1 and Survivin, as potential targets for cancer therapy. The study demonstrated that the combination of ONCONASE and rosiglitazone...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Proteomics Weekly